J 2018

Comparison of Real-time Quantitative Polymerase Chain Reaction and Eight-color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia

HRABOVSKÝ, Štěpán, František FOLBER, J.M. HORACEK, Olga STEHLÍKOVÁ, Hana JELÍNKOVÁ et. al.

Basic information

Original name

Comparison of Real-time Quantitative Polymerase Chain Reaction and Eight-color Flow Cytometry in Assessment of Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia

Authors

HRABOVSKÝ, Štěpán (203 Czech Republic, belonging to the institution), František FOLBER (203 Czech Republic, belonging to the institution), J.M. HORACEK (203 Czech Republic), Olga STEHLÍKOVÁ (203 Czech Republic, belonging to the institution), Hana JELÍNKOVÁ (203 Czech Republic), Cyril SALEK (203 Czech Republic) and Michael DOUBEK (203 Czech Republic, guarantor, belonging to the institution)

Edition

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, DALLAS, CIG MEDIA GROUP, LP, 2018, 2152-2650

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.274

RIV identification code

RIV/00216224:14110/18:00101862

Organization unit

Faculty of Medicine

UT WoS

000448263400013

Keywords in English

ALL; FCM; MRD; Overall survival; Sensitivity

Tags

International impact, Reviewed
Změněno: 4/3/2019 13:11, Mgr. Pavla Foltynová, Ph.D.

Abstract

V originále

We evaluated the usefulness of flow cytometry (FCM) and real-time quantitative polymerase chain reaction (PCR) in the assessment of minimal residual disease (MRD) in adult acute lymphoblastic leukemia. The analysis showed that both FCM and real-time quantitative PCR MRD methods are sensitive for survival prediction during induction. However, FCM was not sufficiently sensitive in later phases of treatment. Background: Minimal residual disease (MRD) is an important prognostic maker in acute lymphoblastic leukemia (ALL). However, few data comparing the measurement of adult ALL MRD using different methods in daily practice are available. We conducted an analysis comparing the importance of flow cytometry (FCM) and real-time quantitative polymerase chain reaction (PCR) in the assessment of MRD in adult ALL. Patients and Methods: Fifty-six consecutive adult patients with both Philadelphia-negative and -positive ALL treated according to an intensive protocol were enrolled in the study. Bone marrow samples were acquired on day 26 and during week 11 of treatment. MRD evaluation was performed using 8-color FCM and PCR of immunoglobulin or T-cell receptor gene clonal rearrangements and BCR-ABL1, KMT2A-AF4 and E2A-PBX1 fusion genes. Results: On day 26, both FCM and PCR seemed to have good discrimination sensitivity for overall survival (P =.001 to.008) and progression-free survival (P =.03 to.04) prediction for both Philadelphia-positive and -negative cases. The most sensitive method in week 11 was PCR including all results > 0 considered to indicate MRD positivity (P =.002 for overall survival and P =.02 for progression-free survival). PCR with other cutoffs was not sufficiently sensitive in week 11. Moreover, no FCM thorn samples were found in week 11. The subanalysis of the Philadelphia-negative patients showed similar results. Conclusion: Our analysis showed that both FCM and PCR MRD assessment methods are sensitive for survival prediction during induction. However, we believe FCM could not be sufficiently sensitive in later phases of treatment. (C) 2018 Elsevier Inc. All rights reserved.

Links

EF16_013/0001634, research and development project
Name: Národní centrum lékařské genomiky - modernizace infrastruktury a výzkum genetické variability populace
EF16_013/0001818, research and development project
Name: Modernizace a podpora výzkumných aktivit národní infrastruktury pro translační medicínu EATRIS-CZ
MUNI/A/1106/2016, interní kód MU
Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit IV (Acronym: VýDiTeHeMA IV)
Investor: Masaryk University, Category A
TE02000058, research and development project
Name: Centrum kompetence pro molekulární diagnostiku a personalizovanou medicínu (Acronym: MOLDIMED)
Investor: Technology Agency of the Czech Republic